Viemed Healthcare (VMD) Q2 2026 earnings summary

Executive summary

• Achieved record quarterly net revenues of $78.1 million, up 24% year-over-year and 4% sequentially, with record ventilator, PAP therapy, and sleep resupply patient counts as of June 30, 2026.

• Net income attributable to shareholders was $2.8 million ($0.07 per diluted share), with Adjusted EBITDA of $13.7 million, down 4% year-over-year due to a prior-year non-recurring gain.

• Growth was driven by ventilation, sleep therapy, resupply, and maternal health service lines, supported by enhanced sales organization and operational capacity.

• Generated $15.9 million in operating cash flow and $8.6 million in free cash flow; repurchased 530,802 shares for $5.1 million and repaid $2.2 million in debt during the quarter.

• CEO highlighted diversified growth engines, strong cash generation, and continued investment in technology and patient care.

Financial highlights

• Q2 2026 revenue reached $78.1 million, up 24% year-over-year; gross profit was $45 million (57.7% margin), and Adjusted EBITDA was $13.7 million (17.6% margin).

• Net income attributable to shareholders was $2.8 million, with diluted EPS of $0.07.

• Free cash flow for the quarter was $8.6 million; trailing twelve months free cash flow totaled $34.4 million.

• Cash and cash equivalents at June 30, 2026, were $10.7 million; working capital was $6.1 million.

• Net capital expenditures for Q2 were $7.3 million (9.3% of revenue).

Outlook and guidance

• Full-year 2026 net revenue guidance raised to $314–$320 million (previously $312–$320 million); Adjusted EBITDA guidance revised to $64–$68 million (previously $65–$69 million).

• Net capital expenditures expected at 8.5%–10.0% of net revenue, lowered from previous guidance.

• Sequential revenue growth anticipated in Q3 and Q4, with Adjusted EBITDA margin expected to remain above 20%.